Module

Prevention and Complementary/Alternative Medicines

Source: Prostate Cancer Annual Update 2006

Prevention and Complementary/Alternative Medicines

Program Director: E. David Crawford, MD

Faculty:
Anne R. Simoneau, MD

CME CREDIT INFORMATION

Release Date: 03/22/06

Expiration Date: 03/21/07

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.1 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe common complementary and alternative therapies, and the rationale, if any, for their use
Summarize the results of large prostate cancer prevention trials and the potential controversies that surround the trials
Discuss staging nomograms and the concept of predicting indolent disease

Topics covered include:

Introduction
Complementary and Alternative Medicines
Potential Mechanisms of CAM Activity on the Prostate
Chemoprevention
Staging and Risk Stratification
Conclusions
Summary—Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.